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Background: Alpha B-crystallin (αB-crystallin) has been suggested to play an important role in the development of
solid tumors. However, the association between αB-crystallin expression and clinicopathological characteristics of
human laryngeal carcinoma is not well defined. This study aimed to examine the expression of αB-crystallin in
human laryngeal squamous cell carcinoma (LSCC) and investigate the relationship between its expression and the
prognosis of LSCC.
Methods: Real-time polymerase chain reaction (six LSCC samples, six tumor-adjacent normal samples) and
immunohistochemistry by tissue microarrays (109 LSCC samples and 28 tumor-adjacent normal samples) were
performed to characterize expression of the αB-crystallin gene in LSCC. Kaplan-Meier survival and Cox regression
analyses were carried out to evaluate the prognosis of LSCC.
Results: Real-time polymerase chain reaction and immunohistochemistry analysis showed that the expression of
αB-crystallin in LSCC was significantly higher than that in tumor-adjacent normal tissues. Moreover, the expression
level of αB-crystallin protein in LSCC was significantly related to alcohol consumption (P = 0.022), tumor
differentiation (P = 0.007), pTNM stage (P = 0.041) and 5 years’ survival (P =0.030). COX multi-factor analysis showed
that αB-crystallin (P = 0.013), as well as pTNM stage (P =0.027) and lymphatic metastasis (P = 0.015) were
independent prognosis factors for LSCC.
Conclusions: The data suggest that αB-crystallin expression is correlated with malignant phenotypes of LSCC and it
may serve as a novel prognostic factor for LSCC.
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Squamous cell carcinoma (SCC) of the head and neck is
one of the most frequent malignancies in the world, with
about a quarter of all cases occurring in the developing
countries. SCC accounts for nearly 90% of all head and
neck carcinomas [1]. Approximately, one-fourth of all
head and neck cancers are laryngeal squamous cell carcin-
oma (LSCC). LSCC is a malignant tumor of laryngeal epi-
thelial origin and the clinical symptoms usually depend on* Correspondence: renjiechenent@yahoo.com.cn; zjsimmons@yahoo.com.cn
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reproduction in any medium, provided the orits original site and size [2,3]. Although several cutting-
edge treatment strategies have been developed for LSCC,
no treatment could achieve a satisfactory therapeutic out-
come and the mortality rate of LSCC is still high (5-year
survival rate is 64%) [4]. Therefore, it is urgent to de-
velop novel and valuable markers to distinguish patients
with poor prognosis or at high risk of early recurrence
and guide chemotherapy and radiotherapy [5].
Alpha B-crystallin (αB-crystallin) is a member of the
small heat shock protein (sHSP) family and acts as a
molecular chaperone, by preventing the aggregation of
denatured proteins after the exposure to stresses such as
heat shock, radiation, oxidative stress and anticancer
drugs [6]. Moreover, ectopic expression of αB-crystallin
in diverse cell types confers protection against a variety
of apoptotic stimuli, including TNF-α, TNF-relatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factor deprivation [7,8]. It is believed that αB-crystallin
can interact with different apoptotic proteins to regulate
apoptosis [9]. Recent studies suggest that αB-crystallin
is a prognostic marker for various types of solid tumors
[10-12]. αB-crystallin may play a role in tumorigenesis
by modulating vascular endothelial growth factor (VEGF)
[13,14]. However, the expression and function of αB-
crystallin in LSCC have not been determined.
In this study, we examined the expression levels of
αB-crystallin in LSCC tissues and tumor-adjacent normal
tissues. The results showed that compared to tumor-
adjacent normal tissues, αB-crystallin expression was
higher in LSCC tissues. In addition, αB-crystallin expres-
sion in LSCC was associated with alcohol consumption,
tumor differentiation, pTNM stage and 5-year survival.
Materials and methods
Patient specimens
A total of one hundred and nine cases of LSCC were col-
lected from the Department of Pathology, the Affiliated
Hospital of Nantong University between 2000 and 2009.
Diagnosis of LSCC was determined according to the
latest WHO criteria [15] and TNM stage classification
(UICC 2002). Among the cases, there were 107 men and
2 women. The mean age of patients at the time of surgery
was 60.8 years (ranging from 29 to 87 years). Related clin-
ical data were collected, including gender, age, tobacco
and alcohol consumption, tumor differentiation, pTNM
stage, lymph node metastasis, and 5-year follow-up sur-
vival. Follow-up in all patients started from post-operation
of May 2010. None of the 109 patients had performed
radiotherapy, chemotherapy or immunotherapy before
the surgery. Study protocol was approved by the Ethics
Committee of Jiangsu Province Official Hospital.
Reverse transcription-polymerase chain reaction (RT-PCR)
and quantitative real-time polymerase chain reaction
analysis (qPCR)
Six samples of fresh LSCC tissues and their adjacent
tissues were collected from the Department of
Otolaryngology-Head and Neck Surgery, the Second
Affiliated Hospital of Nanjing Medical University and
the Department of Otolaryngology-Head and Neck Sur-
gery, Yiji Shan Hospital of Wannan Medical College.
Total RNA was extracted from LSCC tissues and tumor-
adjacent tissues by using Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer's protocol.
RNA (2 μg) was reverse transcribed using High-Capacity
cDNA Archive Kit (Promega) in accordance with the
manufacturer's protocols. Primers were as follows: αB-
crystallin forward 5’-CTTTGACCAGTTCTTCGGAG-
3’, reverse 5’-CCTCAATCACATCTCCCAAC-3’; β-actin
forward 5’- CTCCATCCTGGCCTCGCTGT-3’, reverse5’- GCTGCTACCTTCACCGTTCC-3’. The transcription
levels of β-actin served as a loading control. Analysis of
qPCR was performed using SYBR green dye in an ABI
PRISM 7000HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) following the manu-
facturer’s instructions. Cycle conditions were as follows:
after an initial incubation at 50°C for 2-min and at 95°C
for 10 min, the samples were cycled 40 times at 95°C for
15 seconds and 56°C for 1 min.
Tissue microarrays (TMA) construction and
immunohistochemistry
Formalin-fixed, paraffin-embedded tissues from 109 LSCC
and 28 tumor-adjacent normal tissues were prepared and
utilized in this present study. TMA was produced by
Xinchao Biotech (Shanghai, China). Core tissue biopsies
(2 mm in diameter) were taken from individual paraffin-
embedded LSCC and arranged in the new recipient paraf-
fin blocks. Tissue microarray was cut into 4-μm sections
and placed on super frost charged glass microscope slides.
Paraffin tissue sections (4 μm) were deparaffinized in
100% xylene and re-hydrated in descending ethanol series
and water according to standard protocols. Heat-induced
antigen retrieval was performed in 10 mM citrate buffer
for 2 min at 100°C. Endogenous peroxidase activity was
blocked by hydrogen peroxidase (3%) in Tris-buffered
saline (TBS) for 30 min. Then the sections were boiled
for 10 min in citrate buffer for antigen retrieval. Non-
specific binding was blocked by incubation with 5%
goat serum in TBS for 30 min. Tissue sections were
incubated with mouse anti-αB-crystallin antibody
(Stressgen, Victoria, Canada; 1:300) in TBS containing
1% bovine serum albumin for 1 h. After washing, sec-
tions were incubated with EnVision goat anti-mouse/
horseradish peroxidase antibody (EB-2305, ZhongShan,
Godbridge, China; 1:2000) for 1 h. The replacement of
the primary antibody with PBS served as negative
controls. Finally, the sections were developed with
3,3-diaminobenzidine (DAB) chromogen solution and
counterstained with hematoxylin. Four fields in each
slide were randomly selected and counted, and the
percentage of positive staining was determined by two
clinical pathologists independently using immunohisto-
chemistry score (IHS) [16]. When a conclusion differed,
the final decision was made by consensus. The results
were analyzed according to the method described previ-
ously [17]. Briefly, IHS was determined by the evaluation
of both staining density and intensity. The percentage of
positive tumor cells was scored as follows: 1 (0-10%
positive cells), 2 (11-50% positive cells), 3 (51-80% positive
cells), 4 (81-100% positive cells); and the intensity of stain-
ing was scored as follows: 0 (negative), 1 (weakly positive),
2 (moderately positive), and 3 (strongly positive). Multi-
plication of the intensity and the percentage scores gave
Figure 1 Detection of αB-crystallin mRNA expression in LSCC
tissue and normal tumor-adjacent tissue. Line M: DNA marker
(DL2000, TAKALA, Dalian, China); line 1: LSCC tissues; line 2: normal
tumor-adjacent tissues. Shown were representative images from
three independent experiments.
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low expression of αB-crystallin, and a sum score above
4 indicated high expression of αB-crystallin.
Statistical analysis
The relationship between αB-crystallin expression and
clinicopathological factors was analyzed by chi-squareFigure 2 The mRNA levels of αB-crystallin determined by qPCR. The r
tumor-adjacent tissue (p < 0.05).test. Survival rate was estimated by Kaplan-Meier
method. Univariate and multivariate analysis was carried
out using Cox’s proportional hazards regression models.
For all tests, the significance level for statistical analysis
was set at P < 0.05. Statistical analyses were performed
using STATA Version 12.0 (Stata Corporation, College
Station, TX).Result
High expression of αB-crystallin mRNA in LSCC
RT-PCR amplicons were detected by 1.5% agarose
gel electrophoresis, confirming that αB-crystallin was
expressed in LSCC tissues (Figure 1). Moreover, mRNA
levels of αB-crystallin in LSCC tissues and tumor-
adjacent tissues were determined by qPCR. Normalized
to β-actin, αB-crystallin mRNA level in LSCC tissues
(n = 6) and tumor-adjacent normal tissues (n = 6) was
6.808 ± 1.781 and 2.475 ± 0.757, respectively (t = 5.484,
P = 0.001). mRNA level of αB-crystallin was signifi-
cantly higher in LSCC than in tumor-adjacent normal
tissues (Figure 2).αB-crystallin protein level is correlated with the
clinicopathologic factors of LSCC
By immunohistochemistry analysis, we observed more
positive staining cells and stronger staining in LSCC tis-
sues than in tumor-adjacent normal tissues (Figure 3).
The positive staining was localized mainly in the cyto-
plasm of the tumor cells and strong staining was not
observed in the surrounding tumor-adjacent areas.elative mRNA level of αB-crystallin was higher in LSCC than in normal
Figure 3 Expression pattern of αB-crystallin in tumor tissue and tumor-adjacent tissue of LSCC. TMA sections were analyzed by
immunohistochemical staining. Brown staining indicated positive expression of αB-crystallin. A1-3: The expression pattern of αB-crystallin in
moderately differentiated LSCC tissue. B1-3: The expression pattern of αB-crystallin in well-differentiated LSCC tissue. C1-2: The expression pattern
of αB-crystallin in tumor-adjacent tissue with weakly positive staining of αB-crystallin. C3: Squamous epithelium of adjacent nontumorous tissue
with negative staining of αB-crystallin. Original magnification: ×40 in A1, B1 and C1; ×100 in A2, B2 and C2; ×400 in A3, B3 and C3.
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64 (58.72%) of 109 LSCC samples, while only 5 cases of
28 tumor-adjacent normal tissues (17.86%) displayed
high expression of αB-crystallin. There was significant
difference in high expression rate of αB-crystallin be-
tween LSCC tissues and normal non-cancerous tissues
(P = 0.001).
Correlations between various clinicopathological char-
acteristics and αB-crystallin expression in LSCC tissues
were evaluated by χ2 test (Table 1). The result showed
that high expression of αB-crystallin in LSCC was sig-
nificantly related to alcohol consumption (P = 0.022),
tumor differentiation (P = 0.007), pTNM stage (P = 0.041)
and 5-year survival (P = 0.030). However, no statistically
significant correlation was found between αB-crystallinexpression and gender, age, tobacco use, or lymph node
metastasis.
Survival analysis
Univariate analysis showed that the life span of LSCC
patients was correlated with αB-crystallin expression
(P = 0.010), pTNM stage (P < 0.001), lymph node metas-
tasis (P < 0.001) and tumor differentiation (P = 0.022).
Multivariate analysis with the Cox regression model
indicated that αB-crystallin protein level may serve as
an independent prognostic factor for overall sur-
vival (P = 0.013) (Table 2). Furthermore, pTNM stage
(P = 0.027) and lymph node metastasis (P = 0.015) were
identified as independent predictive factors for poor out-
come of LSCC. Kaplan-Meier survival curves showed
Table 1 Correlation of aB-crystallin expression with
clinicopathological characteristics of LSCC
Groups No. aB-crystallin χ2 P (value)
+ %
Gender
Male 107 63 58.88 0.0638 0.801
Female 2 1 50.00
Age(years)
≤60 y 45 23 51.11 1.8283 0.176
>60 y 64 41 64.06
Tobacco use
Yes 77 42 54.55 1.8816 0.170
No 32 22 68.75
Alcohol consumption
Yes 53 37 69.81 5.2395 0.022*
No 56 27 48.21
Tumor differentiation
Well 51 22 43.14 9.9434 0.007*
Moderate 53 39 71.70
Poor 5 3 80.00
pTNM stage
Stage I, II 65 33 50.77 4.1945 0.041*
Stage III, IV 44 31 70.45
Lymph node metastasis
Yes 19 14 73.68 2.1270 0.145
No 90 50 55.56
Five years’ survival
Yes 72 37 51.39 4.6972 0.030*
No 37 27 72.98
* P < 0.05.
Table 2 Univariate and multivariable analysis of prognostic fa
Univariate analysis
HR p > |z|
αB-crystallin expression
High versus Low 2.508 0.010*
Age (years)
≤60y versus >60y 0.613 0.148
Tobacco use
Yes versus No 0.643 0.203
Alcohol consumption
Yes versus No 0.903 0.747
pTNM stage
Stage I, II versus Stage III, IV 0.291 0.001*
Lymph node metastasis
Yes versus No 4.412 0.001*
Tumor differentiation
Well versus Moderate-Poor 0.478 0.022*
* P < 0.05.
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shorter survival time than patients with low αB-crystallin
expression (Figure 4). Kaplan-Meier survival curves
demonstrated that patients with high αB-crystallin ex-
pression, advanced pTNM stage of LSCC and lymph
node metastasis had a significantly shorter survival time.
Discussion
Several state-of-the-art treatment strategies have been
developed for LSCC, including molecular targeted ther-
apy [18], gene therapy [19] and immunotherapy [20].
However, no treatment could achieve satisfactory thera-
peutic outcome and the survival rate of LSCC has not
been improved significantly [21]. Recent studies suggest
several molecular markers of LSCC [22-24]. Further
identification of prognostic markers for LSCC will be
important for the prevention and therapy of LSCC.
αB-crystallin has been shown to be overexpressed in
numerous kinds of tumors, including gliomas, prostate
cancer, oral squamous cell carcinomas, renal cell carcin-
omas, and head and neck cancer [25]. Recently, an onco-
genic role of αB-crystallin has been proposed for breast
cancer [26]. The neoplastic changes and invasive pheno-
types of breast cells and the anti-apopototic activities
of αB-crystallin were inhibited by the phosphorylation
of αB-crystallin [27,28]. Furthermore, αB-crystallin could
promote tumor angiogenesis by modulating VEGF [13,14].
These studies demonstrate that αB-crystallin plays crucial
role in tumor progression.
In the present study, the mRNA and protein levels of
αB-crystallin in LSCC and tumor-adjacent normal tis-
sues were detected by qPCR and immunohistochemistry.
Both analyses showed that αB-crystallin was highlyctors in LSCC for 5-year survival
Multivariable analysis
95% CI HR p > |z| 95% CI




0.151-0.561 0.426 0.027* 0.200-0.908
2.225-8.748 2.707 0.015* 1.215-6.034
0.255-0.897 0.594 0.107 0.315-1.120
Figure 4 Survival curves of LSCC patients based on various independent factors. A: Overall survival rate in patients with positive expression
of αB-crystallin (red line, αB-crystallin = 1) was significantly lower than that in patients with negative αB-crystallin expression (green line,
αB-crystallin = 0). B: Overall survival rate in patients with stage III-IV of LSCC (red line, stage III-IV = 0) was significantly lower than that in patients
with stage I-II of LSCC (green line, stage I-II = 1). C: Overall survival rate in patients with lymph node metastasis (red line, LN metastasis = 1) was
significantly lower than that in patients without lymph node metastasis (green line, LN metastasis = 0).
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tissues. These results agree with previous report which
showed that αB-crystallin was overexpressed in hepato-
cellular carcinoma cells compared with non-tumour cells
[11]. Moreover, we found that the high expression of
αB-crystallin in LSCC was related to alcohol consumption,
tumor differentiation, pTNM stage and 5-year survival.
Univariate analysis showed that not only αB-crystallin
expression, but also the pTNM stage, lymph node me-
tastasis and tumor differentiation were correlated with
life span of LSCC patients. Multivariate analysis revealed
that strong expression of αB-crystallin could be consid-
ered as an independent factor for poor prognosis of
LSCC patients, as well as pTNM stage and lymph node
metastasis.
Interestingly, several studies suggest that αB-crystallin
acts as a tumor suppressor gene in certain types of cancer
[29-31]. In addition, αB-crystallin staining was reported
to be reduced in head and neck squamous cell carcinoma
and αB-crystallin was not proposed as a prognostic
marker [32,33]. Our present data are inconsistent with
these studies. These conflicting results may be due to
the differences in the pathological samples, the anti-
bodies used, the experimental methods or evaluation
system.
In conclusion, to the best of our knowledge, this is the
first study to report that high αB-crystallin expression is
correlated with aggressive malignant phenotype of LSCC.
Our data indicate that αB-crystallin may serve as a novel
prognostic marker for LSCC. Further studies are needed
to confirm the prognostic and therapeutic value of
αB-crystallin for LSCC.Conclusions
Taken together, the results of this study suggest that
αB-crystallin expression is correlated with malignant
phenotypes of LSCC and it may serve as a novel
prognostic factor for LSCC.Competing interests
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